ProgesteroneCrinone

6.1 The PBAC recommended the Authority Required (STREAMLINED) listing of progesterone capsule 300 mg (Utrogestan) BID on the basis it should be available only under special arrangements covered under the PBS section 100 (IVF Program) for LPS as part of an ART treatment cycle.PSD · Jul 2024

6.2 The PBAC did not consider it appropriate to cost-minimise based on an equivalent price per day of treatment. The PBAC advised that the CMA should be calculated at an equivalent price per treatment course and noted that the sponsor accepted this in its pre-PBAC response.PSD · Jul 2024

5.21 As a Category 4 submission, the economic analysis has not been independently evaluated. 4PSD · Jul 2024

5.22 The submission presented a cost-minimisation approach (CMA) of progesterone capsule 300 mg BID compared with progesterone capsule 200 mg TID.PSD · Jul 2024

5.19 The submission claimed the non-inferior comparative effectiveness and non-inferior comparative safety of progesterone capsule 300 mg BID compared with progesterone capsule 200 mg TID.PSD · Jul 2024

5.20 The PBAC considered that the claim of non-inferior comparative effectiveness and non-inferior comparative safety was reasonable.PSD · Jul 2024

4.3 The requested amendment for a maximum quantity of 45 pessaries with 3 repeats for Oripro would reduce the number of patient co-payments from 6 to 4. Currently, the total co-payment costs for Oripro is $247.80 for 6 months of treatment (general patient) compared with $165.20 for a general patient on Utrogestan.PSD · Nov 2021

4.7 Based on the requested amendments to the Oripro (prevention of preterm birth) listing, the submission estimated there would be a net cost to the PBS/RPBS of $0 to < $10 million over six years. The loss in average co-payments per patient ($38.43) offsets the save from the reduction in DPMQ per patient (-$13.27). This results in a net cost per patient of $25.16 and hence the net cost to the PBS/RPBS of $0 to < $10 million over six years. 4PSD · Nov 2021